Sanofi MS drug Lemtrada misses a goal in study BusinessWeek French drugmaker Sanofi said Monday that its multiple sclerosis drug candidate Lemtrada did not achieve one of its goals in a late-stage clinical trial. Sanofi said Lemtrada worked better than an older drug, Rebif, in preventing relapses, ... See all stories on this topic » |
Poor bone health may start early in people with multiple sclerosis EurekAlert (press release) Osteoporosis and low bone density are common in people in the early stages of multiple sclerosis (MS), according to a new study published in the July 12, 2011, print issue of Neurology®, the medical journal of the American Academy of Neurology. ... See all stories on this topic » |
Women's group turned my life around, says MS victim Oxford Mail Gill Miles, of Chadlington, said women's group Eve has helped her recover from isolation and depression caused by Multiple Sclerosis. Eve meets once a week to offer support for women going through crisis, including domestic violence and bereavement. ... See all stories on this topic » |
Multiple sclerosis treatment blocks faulty white blood cells Barchester Healthcare A treatment developed in the US may present a way to cure or slow multiple sclerosis. A new treatment from the Scripps Research Institute in Florida has been found to halt multiple sclerosis in mice, raising hope that a similar method may be applicable ... See all stories on this topic » |
How Safe Could Intrathecal Transplantation of Mesenchymal Stem Cells Be ... Archives of Neurology We read with considerable interest the exploratory study by Karussis et al 1 on the safety of intrathecally transplanted mesenchymal stem cells (MSCs) in patients with multiple sclerosis (MS) and those with amyotrophic lateral sclerosis (ALS). ... See all stories on this topic » |
|
|
Phase 3 Study of Lemtrada for Multiple Sclerosis - MPR Sanofi and Genzyme announced results from its CARE-MS 1 study of Lemtrada (alemtuzumab) for the treatment of multiple sclerosis. Latest articles from MPR |
Sanofi Reports Positive Top-Line Results from First Phase 3 Study ... 55 percent relapse rate reduction over and above high dose IFN -1a in treatment na ve MS patients - Jul 11, 2011 - Sanofi (EURONEXT SAN and NYSE SNY) and its. Drugs.com - Clinical Trials |
Will Cinnamon Slow Multiple Sclerosis? - The People's Pharmacy® Researchers at Rush University Medical Center are launching a study in mice that may indicate whether cinnamon might help treat multiple sclerosis. ... www.peoplespharmacy.com/.../will-cinnamon-slow-multiple-s... |